

JC10 Rec'd PCT PTO 21 JUL 2005

PCT #5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Group Art Unit 1615

In re

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

Patent Application of

Yung-Hi Kim, et al.

Serial No.: 10/509,300

Filed: Unknown

Confirmation No.: 3663

Examiner: Not Yet Assigned

I, Anna Poppe, hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date of my signature.

Signature

Date of Signature

"NOVEL THERAPEUTICAL USE OF AGONIST
LIGANDS SPECIFIC TO G2A RECEPTOR"

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES UNDER 37
CFR § 1.821(g) AND
STATEMENT UNDER 37 CFR § 1.821(f)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

This is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures, mailed June 17, 2005. Applicants enclose herewith a copy of the Notice.

Applicants submit herewith a copy of the Sequence Listing in computer readable form (on 3.5" diskette prepared in Dos Text format).

In accordance with 37 CFR § 1.821(g), the undersigned avers that the content of the computer readable form of the Sequence Listing provided on the enclosed 3.5" diskette is the same as the Sequence Listing in written form and that the submission includes no new matter.

Respectfully submitted,


Wendy M. Seffroed
Reg. No. 52,205

File No. 013709-9001-US00

Michael Best & Friedrich LLP
One South Pinckney Street
P.O. Box 1806
Madison, WI 53701-1806
(608) 257-3501

Q:\client\013709\9001\B0598938.1



UNITED STATES PATENT AND TRADEMARK OFFICE

Rec'd PCT/PTO 21 JUL 2005 Page 1 of 2

013709 - 9001

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/509,300	Yung-Hi Kim	OPA9408-32/US

23510
MICHAEL BEST & FRIEDRICH, LLP
ONE SOUTH PINCKNEY STREET
P O BOX 1806
MADISON, WI 53701

Michael Best & Friedrich LLP

RECEIVED

JUN 20 2005

INTERNATIONAL APPLICATION NO.

PCT/KR03/00593

FILING DATE

03/25/2003

PRIORITY DATE

03/25/2002

CONFIRMATION NO. 3662

DOCKETING 371 FORMALITIES LETTER
MADISON, WI

OC000000016306909*

Date Mailed: 06/17/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES*deducted for 8/17/05 023W*Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/509,300	PCT/KR03/00593	OPA9408-32/US

FORM PCT/DO/EO/922 (371 Formalities Notice)